Topical Cyclosporine and Disease Progression
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60641
- Lakeside Eye Clinic
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Mild to Moderate dry eye symptoms
Exclusion Criteria:
- Current use of Restasis
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: 2.
|
Restasis- (in the eye) Instill one drop twice daily Endura- (in the eye) Instill one drop twice daily
|
|
Active Comparator: 1.
|
Restasis- (in the eye) Instill one drop twice daily Endura- (in the eye) Instill one drop twice daily
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Disease Severity
Time Frame: 1 yr
|
1 yr
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Staining
Time Frame: 1 yr
|
1 yr
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Sanjay Rao, Lakeside Eye Clinic
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Disease Attributes
- Disease Progression
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antirheumatic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Dermatologic Agents
- Antifungal Agents
- Calcineurin Inhibitors
- Cyclosporine
- Cyclosporins
Other Study ID Numbers
Other Study ID Numbers
- 13717A
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Disease Progression
-
NCT04811950Not yet recruiting
-
NCT06306170RecruitingGynecologic Cancer | Radiotherapy Side Effect | Survivorship | Radiotherapy; Complications | Progression, Disease | Progression, Clinical
-
NCT06826092RecruitingProgression-Free Survival
-
NCT01453257CompletedProgression Free Survival
-
NCT02643342Completed
-
NCT02623543Unknown
-
NCT02643875Completed
-
NCT06708156Recruiting
-
NCT05700240CompletedMyopia Progression
Clinical Trials on Restasis
-
NCT00407043CompletedKeratoconjunctivitis Sicca | Dry Eye Disease
-
NCT03597139Completed
-
NCT00405431Completed
-
NCT02461719Completed
-
NCT03666884Completed
-
NCT04795752CompletedDry Eye | Meibomian Gland Dysfunction